|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.776 USD | +1.44% |
|
+2.12% | +2.11% |
| 05-21 | Phio Pharmaceuticals Files $100 Million Mixed Shelf | MT |
| 05-15 | Phio Pharmaceuticals Doses 1st Group in Skin Cancer Treatment Study | MT |
Phio Pharmaceuticals Corp. announced the departure of Dr. Gerrit Dispersyn from his role as Chief Executive Officer. Dr. Dispersyn joined the company in 2017 as Chief Development Officer and was subsequently appointed President and CEO in March 2019.
During his tenure as CEO Gerrit continued it's transition to become an immuno-oncology based enterprise originally initiated by Dr. Geert Cauwenbergh.
| 1st Jan change | Capi. | |
|---|---|---|
| +2.11% | 3.51M | |
| +54.05% | 63.85B | |
| -2.02% | 41.83B | |
| +40.01% | 40.47B | |
| -10.22% | 27.17B | |
| +13.42% | 26.52B | |
| -21.60% | 18.69B | |
| +2.89% | 12.73B | |
| +22.40% | 12.11B | |
| +27.49% | 12.07B |
PHIO PHARMACEUTICALS CORP. 
